세계의 유도만능줄기세포(iPSC) 생산 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 프로세스별, 제품 유형별, 용도별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

Induced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Process, By Product, By Application, By End-user, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,169,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,541,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 10,968,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 유도만능줄기세포(iPSC) 생산 시장은 2024년 13억 5,000만 달러로 평가되었고, 2030년에는 24억 5,000만 달러에 이를 것으로 예측되며, 예측 기간 동안 10.44%의 연평균 성장률(CAGR)로 성장할 전망입니다.

iPSC는 자가 재생 및 여러 세포 유형으로 분화할 수 있는 능력으로 인해 재생 의학 분야에서 획기적인 혁신으로 부상하고 있습니다. 피부나 혈액에서 추출한 세포와 같은 성체 세포를 재프로그래밍하여 추출한 iPSC는 배아 줄기세포와 유사한 특성을 보이는 동시에 기존 원천과 관련된 윤리적, 면역학적 문제를 해결합니다. 이러한 다용도성 덕분에 재생 치료, 약물 스크리닝, 질병 모델링에 중요한 도구로 자리매김하고 있습니다. 신경학, 심장학, 대사 장애 전반에 걸친 응용 분야의 증가에 힘입어 iPSC 기술이 발전함에 따라 시장은 빠르게 확장되고 있습니다. 개인 맞춤형 의학으로의 전환과 성인 유래 세포 사용의 윤리적 이점은 수요를 더욱 강화하여 차세대 생의학 연구 및 치료제 개발의 초석으로 iPSC를 자리매김하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	13억 5,000만 달러
시장 규모(2030년)	24억 5,000만 달러
CAGR(2025-2030년)	10.44%
급성장 부문	신약 개발 및 발견
최대 시장	북미

시장 성장 촉진요인

치료 용도 확대

주요 시장 과제

생산 비용

주요 시장 동향

질병 모델링 및 신약 개발에서의 용도 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 인공 다능성 줄기 세포 생산 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 프로세스별(수동 iPSC 생산 프로세스, 자동 iPSC 생산 프로세스)
  • 제품 유형별(기기 및 디바이스, 자동화 플랫폼, 소모품 및 키트, 서비스)
  • 용도별(신약 개발 및 발견, 재생 의학, 독성학 연구, 기타)
  • 최종 사용자별(연구 및 학술기관, 생명공학 및 제약회사, 병원 및 클리닉)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 유도만능줄기세포 생산 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 유도만능줄기세포 생산 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 인공 다능성 줄기 세포 생산 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 유도만능줄기세포 생산 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 유도만능줄기세포 생산 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 최근 동향
• 제품 출시
• 합병 및 인수

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Lonza Group
• Axol Biosciences Ltd.
• Evotec SE
• Hitachi Ltd.
• Reprocells Inc.
• Fate Therapeutics.
• Thermo Fisher Scientific, Inc.
• Merck KgaA
• Stemcellsfactory III
• Applied Stemcells Inc.

제16장 전략적 제안

제17장 기업 소개와 면책사항

HBR

영문 목차

영문목차

The Global Induced Pluripotent Stem Cells (iPSCs) Production Market was valued at USD 1.35 billion in 2024 and is projected to reach USD 2.45 billion by 2030, growing at a CAGR of 10.44% during the forecast period. iPSCs have emerged as a transformative innovation in regenerative medicine due to their ability to self-renew and differentiate into multiple cell types. Derived by reprogramming adult cells like those from skin or blood, iPSCs exhibit properties similar to embryonic stem cells while addressing ethical and immunological concerns associated with traditional sources. Their versatility positions them as vital tools for regenerative therapies, drug screening, and disease modeling. With advancements in iPSC technology, the market is expanding rapidly, driven by growing applications across neurology, cardiology, and metabolic disorders. The shift towards personalized medicine and the ethical benefits of using adult-derived cells further bolster demand, establishing iPSCs as a cornerstone in next-generation biomedical research and therapeutic development.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.35 Billion
Market Size 2030	USD 2.45 Billion
CAGR 2025-2030	10.44%
Fastest Growing Segment	Drug Development and Discovery
Largest Market	North America

Key Market Drivers

Expanding Therapeutic Applications

The potential of iPSCs in clinical therapy is continuously growing as they are applied to an expanding spectrum of diseases. Their ability to differentiate into various specialized cell types makes them highly promising for treating complex conditions such as Parkinson's disease, Alzheimer's, cardiovascular disorders, and diabetes. iPSCs derived from adult cells can be engineered into dopaminergic neurons, offering targeted treatment pathways and facilitating drug development for neurodegenerative conditions. Similarly, their application in cardiac regeneration is gaining traction, with researchers using iPSC-derived cardiac cells to model heart diseases and explore regenerative options post-injury. The increasing adoption of iPSCs in these therapeutic areas not only enhances treatment potential but also broadens the market for their production, as healthcare systems and patients alike seek advanced, tailored solutions.

Key Market Challenges

Cost of Production

A major limitation hindering the widespread adoption of iPSC technologies is the high cost associated with their generation and maintenance. The reprogramming of adult cells into iPSCs involves resource-intensive processes that require high-end laboratory infrastructure, advanced equipment, and skilled personnel. Furthermore, the culture media and reagents used in iPSC production are costly and must comply with strict quality standards to ensure consistency and safety. These operational expenses create significant financial barriers for both academic and commercial entities attempting to scale production for therapeutic use. Consequently, the cost of iPSC-based therapies remains high, limiting accessibility for broader patient groups and posing challenges for market scalability.

Key Market Trends

Growing Applications in Disease Modeling and Drug Development

The increasing use of iPSCs in disease modeling and pharmaceutical research is a key trend driving market growth. iPSCs can be generated from individuals with specific genetic profiles, enabling the creation of personalized disease models. These models provide valuable platforms for understanding disease mechanisms and testing drug responses in conditions such as genetic disorders, neurodegenerative diseases, and cardiovascular anomalies. Pharmaceutical companies are leveraging iPSC technology to enhance drug discovery pipelines, enabling more accurate candidate screening and reducing development timelines and costs. The rising emphasis on precision medicine further amplifies the need for iPSC-derived models, reinforcing their significance in both academic research and commercial drug development.

Key Market Players

• Lonza Group
• Axol Biosciences Ltd.
• Evotec SE
• Hitachi Ltd.
• Reprocells Inc.
• Fate Therapeutics.
• Thermo Fisher Scientific, Inc.
• Merck KgaA
• Stemcellsfactory III
• Applied Stemcells Inc.

Report Scope:

In this report, the Global Induced Pluripotent Stem Cells Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Induced Pluripotent Stem Cells Production Market, By Process:

• Manual iPSC Production Process
• Automated iPSC Production Process

Induced Pluripotent Stem Cells Production Market, By Product:

• Instruments/ Devices
• Automated Platforms
• Consumables & Kits
• Services

Induced Pluripotent Stem Cells Production Market, By End-user:

• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics

Induced Pluripotent Stem Cells Production Market, By Application:

• Drug Development and Discovery
• Regenerative Medicine
• Toxicology Studies
• Others

Induced Pluripotent Stem Cells Production Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Production Market.

Available Customizations:

Global Induced Pluripotent Stem Cells Production market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Induced Pluripotent Stem Cells Production Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Process (Manual iPSC Production Process, Automated iPSC Production Process)
  • 5.2.2. By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services)
  • 5.2.3. By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others)
  • 5.2.4. By End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Induced Pluripotent Stem Cells Production Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Process
  • 6.2.2. By Product
  • 6.2.3. By End-user
  • 6.2.4. By Application
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Induced Pluripotent Stem Cells Production Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Process
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By End-user
      • 6.3.1.2.4. By Application
  • 6.3.2. Mexico Induced Pluripotent Stem Cells Production Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Process
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By End-user
      • 6.3.2.2.4. By Application
  • 6.3.3. Canada Induced Pluripotent Stem Cells Production Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Process
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By End-user
      • 6.3.3.2.4. By Application

7. Europe Induced Pluripotent Stem Cells Production Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Process
  • 7.2.2. By Product
  • 7.2.3. By End-user
  • 7.2.4. By Application
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Induced Pluripotent Stem Cells Production Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Process
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By End-user
      • 7.3.1.2.4. By Application
  • 7.3.2. Germany Induced Pluripotent Stem Cells Production Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Process
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By End-user
      • 7.3.2.2.4. By Application
  • 7.3.3. United Kingdom Induced Pluripotent Stem Cells Production Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Process
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By End-user
      • 7.3.3.2.4. By Application
  • 7.3.4. Italy Induced Pluripotent Stem Cells Production Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Process
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By End-user
      • 7.3.4.2.4. By Application
  • 7.3.5. Spain Induced Pluripotent Stem Cells Production Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Process
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By End-user
      • 7.3.5.2.4. By Application

8. Asia-Pacific Induced Pluripotent Stem Cells Production Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Process
  • 8.2.2. By Product
  • 8.2.3. By End-user
  • 8.2.4. By Application
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Induced Pluripotent Stem Cells Production Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Process
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By End-user
      • 8.3.1.2.4. By Application
  • 8.3.2. India Induced Pluripotent Stem Cells Production Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Process
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By End-user
      • 8.3.2.2.4. By Application
  • 8.3.3. South Korea Induced Pluripotent Stem Cells Production Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Process
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By End-user
      • 8.3.3.2.4. By Application
  • 8.3.4. Japan Induced Pluripotent Stem Cells Production Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Process
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By End-user
      • 8.3.4.2.4. By Application
  • 8.3.5. Australia Induced Pluripotent Stem Cells Production Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Process
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By End-user
      • 8.3.5.2.4. By Application

9. South America Induced Pluripotent Stem Cells Production Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Process
  • 9.2.2. By Product
  • 9.2.3. By End-user
  • 9.2.4. By Application
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Induced Pluripotent Stem Cells Production Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Process
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By End-user
      • 9.3.1.2.4. By Application
  • 9.3.2. Argentina Induced Pluripotent Stem Cells Production Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Process
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By End-user
      • 9.3.2.2.4. By Application
  • 9.3.3. Colombia Induced Pluripotent Stem Cells Production Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Process
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By End-user
      • 9.3.3.2.4. By Application

10. Middle East and Africa Induced Pluripotent Stem Cells Production Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Process
  • 10.2.2. By Product
  • 10.2.3. By End-user
  • 10.2.4. By Application
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Induced Pluripotent Stem Cells Production Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Process
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By End-user
      • 10.3.1.2.4. By Application
  • 10.3.2. Saudi Arabia Induced Pluripotent Stem Cells Production Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Process
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By End-user
      • 10.3.2.2.4. By Application
  • 10.3.3. UAE Induced Pluripotent Stem Cells Production Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Process
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By End-user
      • 10.3.3.2.4. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Lonza Group
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Axol Biosciences Ltd.
• 15.3. Evotec SE
• 15.4. Hitachi Ltd.
• 15.5. Reprocells Inc.
• 15.6. Fate Therapeutics.
• 15.7. Thermo Fisher Scientific, Inc.
• 15.8. Merck KgaA
• 15.9. Stemcellsfactory III
• 15.10. Applied Stemcells Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료